Winners of Joensuu (Finland) City Challenge Innovation Competition Are Announced: Smart City Apps and Surfing among the Winners
The winners of the innovation competition organised by the City of Joensuu, Finland have been chosen. Four solutions will be implemented in Joensuu city centre during the next 12 months, developed by Parquery from Switzerland, Leapcraft from Denmark, Risto Takala consortium from Joensuu, Finland, and Ctrl4 Enviro from Spain. The chosen cases range from city lab approach to computer vision applications for parking space detection, traffic and crowd monitoring as well as energy optimisation in a swimming pool. In addition, an artificial surf wave will be tested in the river running through the town centre.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180528005231/en/
Winners of Joensuu (Finland) City Challenge Innovation Competition Are Announced: Smart City Apps and Surfing among the Winners (Photo: Business Wire)
The City of Joensuu’s innovation competition searched for feasible solutions for four different challenges, each with a budget of 50,000 euros. There were 19 submissions in total.
Valuable opportunity for companies
In the City Lab Approach, Leapcraft’s solution provides and communicates comprehensive information about the air quality, traffic and weather conditions such as wind speed and direction. “Our ambition is to help Nordic and global cities to improve air quality and implement new technology, and we saw this competition as a good opportunity to do so. We look forward to the opportunity to deploy our solution in a new interesting city”, said Operations Manager Anne Cecilie Duus Kühnel from Leapcraft.
Parquery’s computer vision -based application provides real-time information about parking and free parking spaces. Parquery is a spin-off from ETH Zürich. “Winning the competition is extremely valuable for us, in particular by giving us the opportunity to showcase our solution in the City of Joensuu. We believe that the Finnish market is extremely advanced in terms of smart cities and therefore an ideal target market for Parquery”, says Andrea Fossati, CEO of Parquery.
The artificial surf wave is based on a patent of Aalto University, Helsinki, Finland, and will be the first of its kind to be tested. The wave would make Joensuu a unique surf destination. “We are happy that the City of Joensuu is bold enough to also support a bit more daring innovation”, say Risto Takala and Jarmo Laine who are behind the artificial wave proposal.
Ctrl4 Enviro’s computer vision -based application will result in a smart swimming pool and smart market square. The real time data on the user amounts enable to optimize the energy, water and chemical consumption in swimming pool – and the activities in the market square.
Vision and city behind the innovation competition
City of Joensuu arranged the competition in order to find new and innovative solutions for developing the city and public services. In addition, City of Joensuu wants to boost region’s innovativeness and internationality through public procurement and cooperation. The initiative is supported by the Urban Growth Agreement of the Finnish Government and especially the Ministry of Economic Affairs and Employment.
Joensuu is a university town and growing regional centre in the eastern part of Finland. The town has one of the most ambitious climate targets in Europe: to be carbon neutral by 2025. One third of the population is less than 25 years old and there are more than 20,000 students in the town. City population totals up to 76,000 and that of the nearby region 120,000. Joensuu core competencies are forest bioeconomy, education, photonics, ICT, metal industries and new materials. European Forest Institute, an international science-based organisation is also located in Joensuu. The town has a strong policy for innovative public procurement, investments and solutions.
Joensuu is located in the heart of the Finnish Lakeland, and lies on the waterfront and in the middle of dense forests. Core of the town is a vibrant pedestrian area and market square, which is currently undergoing a major renovation. In this part of the world weather conditions include four seasons, and snow cover lasts on average five months. In the summer it hardly gets dark, and the official Finnish heat record of 37.2 degrees Celsius was measured at Joensuu airport in 2010.
Official address of the competition procedure: firstname.lastname@example.org
Competition web page: www.joensuu.fi/challenge
|+41 76 234 2948|
Anne Cecilie Duus Kühnel
|+45 5098 4728|
|+34 93586 8760|
|+358 50490 4598|
|+358 40751 3042|
The City of Joensuu
Dr. Janna Puumalainen, +358 50 5115028
Director of Strategy
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu